European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 
02 Sep 2008

Changes in clinical, neurohormonal, electrolyte, renal, hematological and hepatic profiles during and after hospitalization for acute decompensated heart failure: Analysis from the EVEREST trial. 

Clinical Trial Update II

Topics: Heart Failure (HF)
Session number: 3273-3274
Session title: Clinical Trial Update II
Authors: Gheorghiade, Mihai  & Tendera, Michal

Mihai GheorghiadePresenter report:

Gheorghiade, Mihai (United States of America)Watch webcast

Patients admitted with Acute Heart Failure Syndromes (AHFS) have a post-discharge mortality and re-hospitalization that can be as high as 15% and 30%, respectively, within 60-90 days post-discharge. The clinical and laboratory profiles of these patients in the early post-discharge phase have not been well studied. Identifying potential targets for therapy during the immediate post-discharge period is important in order to reduce the high event rate. 


 
Objectives: 
The objectives of this retrospective analysis of prospectively collected data were 1) to establish the clinical, electrolyte, renal, hepatic, and neurohormonal profile post-discharge in patients who died or were re-hospitalized within 3 months, within 3-12 months, and those with no events at 1 year post-discharge, and 2) to determine the prognostic value of post-discharge clinical and laboratory parameters for mortality and readmission.

Methods:  The EVEREST trial randomized 4133 patients admitted with worsening HF and an ejection fraction (EF) <40% to oral tolvaptan versus placebo in addition to standard therapy.  Patients were followed for a median of 9.9 months.  During hospitalization and post-discharge, the following parameters were collected prospectively on hospital day 1, day 7 or discharge, post-discharge weeks 1, 4, 8, and then every 8 weeks thereafter:  blood pressure (BP), heart rate (HR), body weight, serum sodium, potassium, magnesium, blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), liver function and B-type natriuretic peptide (BNP) or N-terminal pro-BNP, aldosterone, arginine vasopressin (AVP).

Results:  Post-discharge signs and symptoms of HF resulting from abnormal hemodynamics, as well as neurohormonal and renal abnormalities appear to predict high early post-discharge mortality and re-hospitalization rates, in spite of evidence-based therapies (ACEI/ARB, BB, Aldosterone-blocking agents). In the multivariate time-dependent analysis, the major post-discharge predictor for early mortality was worsening renal function (change in BUN). An increase in body weight was the major predictor for early re-hospitalization. This data suggests new therapies aimed at safely improving hemodynamics, neurohormonal profile, and renal function are needed.


Discussant: Tendera, Michal (PolandWatch webcast)

  


The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.